Answers are grounded in this paper and cite their sources.
Clinical trial outlines baseline profiles of chronic kidney disease patients receiving dapagliflozin, highlighting broad enrollment across diverse kidney etiologies.
Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.
No takes yet. Share an insight, caveat, or question.
Wheeler et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: